Welcome to our dedicated page for Neuroone Med Technologies SEC filings (Ticker: NMTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a medical technology issuer focused on minimally invasive, high-definition EEG, ablation, drug delivery and brain stimulation solutions for neurological disorders, NeuroOne uses its SEC reports to present detailed information on its financial condition, operations, risks and material events.
Here you can review NeuroOne’s current reports on Form 8-K, which the company uses to announce events such as quarterly and annual financial results, preliminary revenue figures, FDA 510(k) clearances for devices like the OneRF Trigeminal Nerve Ablation System, capital raising activities and notices related to Nasdaq listing requirements. These filings often incorporate or reference press releases that describe product performance, regulatory milestones and developments in programs including the OneRF Ablation System, spinal cord stimulation initiatives and sEEG-based drug delivery.
In addition to 8-Ks, investors can consult NeuroOne’s periodic reports on Forms 10-Q and 10-K (when available) for comprehensive financial statements, management’s discussion and analysis, and risk factor disclosures tied to its neuromodulation and surgical appliance business. The company has also filed updates related to its at-the-market offering program, distribution agreements and other capital markets activities, which are documented in its SEC submissions.
Stock Titan enhances these NMTC filings with AI-powered summaries that highlight key points, such as revenue trends, gross margin changes, cash position commentary, regulatory updates and listing compliance discussions. Users can quickly identify items like FDA clearance announcements, preliminary annual revenue disclosures and Nasdaq minimum bid price notices, then drill into the full documents for deeper analysis. This page is designed to help investors, analysts and other interested readers efficiently navigate NeuroOne’s official SEC record.
NeuroOne Medical Technologies Corporation held its annual stockholder meeting and approved several key proposals, including a potential reverse stock split and changes to its equity incentive plan. Stockholders authorized the Board to implement a reverse stock split in a range from 1-for-2 to 1-for-15 of the outstanding common stock.
Two Class III directors, Jeffrey Mathiesen and Edward Andrle, were elected to three-year terms ending at the 2029 annual meeting. Stockholders also ratified Baker Tilly US, LLP as independent registered public accounting firm for the fiscal year ending September 30, 2026, and approved an amendment to the 2025 Equity Incentive Plan. A total of 30,272,834 shares, representing approximately 59.72% of shares outstanding as of the record date, were present in person or by proxy.
NeuroOne Medical Technologies officer Mark Christianson reported recent transactions in the company’s Common Stock. On March 30, he completed an open-market sale of 15,363 shares at $0.74 per share. On March 31, an additional 253 shares were disposed of as a tax-withholding transaction, covering tax obligations rather than representing a market trade.
Following these transactions, Christianson holds 198,667 shares of NeuroOne Common Stock directly, according to the filing. The activity reflects a net reduction in his position, primarily driven by the open-market sale, with the smaller tax-withholding disposition tied to equity-related compensation.
NEUROONE MEDICAL TECHNOLOGIES Corp Chief Technology Officer Steve Mertens reported a small share disposition related to taxes, not an open-market trade. On this Form 4, 906 shares of common stock were withheld at $0.777 per share to satisfy a tax obligation. Following this tax-withholding disposition, Mertens directly holds 152,141 shares of common stock.
NEUROONE MEDICAL TECHNOLOGIES Corp director and CEO David A. Rosa reported a tax-related share disposition. On the reported date, 2,458 shares of Common Stock were delivered at $0.777 per share as a tax-withholding disposition to cover exercise price or tax liabilities. After this non-market transaction, he directly owned 1,080,132 shares of Common Stock.
NEUROONE MEDICAL TECHNOLOGIES Corp executive Mark Christianson, Business Development Director, reported small open-market sales of company common stock. He sold 817 shares on March 12, 2026 and 100 shares on March 13, 2026, both at $0.80 per share. After these transactions, he directly holds 214,283 shares of NeuroOne common stock.
NEUROONE MEDICAL TECHNOLOGIES Corp officer Mark Christianson reported open-market sales of a total of 13,720 shares of common stock at weighted average prices around $0.80 per share on March 10–11, 2026. After these transactions, he directly holds 215,200 shares of common stock.
NeuroOne Medical Technologies Corporation is asking stockholders to vote at its April 3, 2026 annual meeting on key governance and capital-structure items. Routine matters include electing two Class III directors, ratifying Baker Tilly US, LLP as auditor, and amending the 2025 Equity Incentive Plan.
The most significant proposal would authorize the Board to implement a reverse stock split at a ratio between 1-for-2 and 1-for-15 any time within one year, primarily to help regain compliance with Nasdaq’s $1.00 minimum bid price requirement. The split would reduce outstanding shares but leave authorized shares unchanged, increasing the number of authorized, unissued shares.
The equity plan amendment would add 1,500,000 shares to the 2025 Equity Incentive Plan and introduce a five-year “evergreen” feature allowing annual increases of up to 5% of fully diluted shares from 2027 through 2031. Stockholders are also asked to approve the ability to adjourn the meeting to solicit more proxies if needed for the reverse split proposal.
NEUROONE MEDICAL TECHNOLOGIES Corp’s Chief Business Officer, David J. Wambeke, reported acquiring both stock options and common shares. On March 1, 2026, he received an option to purchase 500,000 shares of common stock at an exercise price of $0.00 per share. According to the terms, 25% of this option will vest on March 1, 2027, with the remaining 75% vesting in 12 equal quarterly installments starting March 31, 2027. On the same date, he also made an open-market purchase of 1,000,000 shares of common stock at a price of $0.6704 per share, bringing his directly owned common stock position to 1,000,000 shares.